Precision medicine oncology company IDEAYA Biosciences Inc (Nasdaq:IDYA) on Sunday announced the development candidate nomination of IDE101, a potential first-in-class dual cyclin-dependent kinase (CDK) inhibitor designed to address the loss of CDKN2A-mediated tumour suppressor function in cancer.
CDKN2A-deficiency occurs in approximately 10-15% of all solid tumours, including around 70% of pancreatic ductal adenocarcinoma (PDAC), and is typically co-deleted in methylthioadenosine phosphorylase (MTAP)-deficient cancers given their proximity on chromosome 9p21.
IDEAYA says that IDE101 was discovered through its iterative physics-based ligand design and optimisation platform, and is a highly potent and selective dual CDK inhibitor with first-in-class potential and favourable drug-like properties. IND-enabling studies for IDE101 are ongoing to support an Investigational New Drug (IND) filing to the US Food and Drug Administration (FDA) in the first half of 2027, subject to satisfactory completion of ongoing preclinical and IND-enabling studies.
Ascletis announces submission of US IND application for oral obesity combination therapy
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Compass Pathways completes FDA application for COMP360 in treatment-resistant depression
bioMérieux secures FDA clearance for updated gastrointestinal diagnostic panels
Photocure maintains 2028 Medicare coverage target for AssureMDx following CMS update
Johnson & Johnson reveals new Phase 2 nipocalimab study data in Sjögren's disease
SK Biopharmaceuticals submits cenobamate supplemental New Drug Application to US FDA
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
United Therapeutics eliminates Pfizer royalty obligations on ralinepag for USD525m
Pentixapharm advances preparationsfor Phase 3 PANDA study
StimLabs launches DermaForm collagen scaffold particulate device
Merck launches Phase 3 trial of Ohtuvayre for COPD exacerbation prevention